Skip to main content

Table 2 Univariate analysis of pathological type, Ki67, therapeutic regimen, and prognosis of MPM patients

From: Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients

Variables Median survival time (month), 95% CI P value
All patients 12 (9.7~14.3)  
History of asbestos exposure
 No 12 (4.6~19.4) 0.537
 Yes 11 (7.8~14.3)  
T staging
 T3 12 (9.5~14.5) 0.023
 T4 6 (4.7~7.3)  
Pathological type   0.005
 Epithelioid 12 (10.1~13.9)  
 Sarcomatoid 5 (2.0~9.8)
Ki67   0.036
 ≤10% 15 (12.1~17.9)  
 >10% 11 (7.1~14.9)  
Therapeutic regimen   <0.001
 G1 6 (3.8~8.2)  
 G2 11 (3.7~18.3)  
 G3 12 (8.0~16.0)  
 G4 24 (20.0~28.0)  
  1. G1 peritoneal biopsy (or adnexectomy) combined with paclitaxel + platinum perfusion, G2 peritoneal biopsy (or adnexectomy) combined with pemetrexed + platinum perfusion, G3 cytoreductive surgery combined with paclitaxel + platinum perfusion, G4 cytoreductive surgery combined with pemetrexed + platinum perfusion